BR112022003713A2 - Multímeros de fc de igg recombinantes para o tratamento de doenças renais mediadas por imunocomplexo - Google Patents

Multímeros de fc de igg recombinantes para o tratamento de doenças renais mediadas por imunocomplexo

Info

Publication number
BR112022003713A2
BR112022003713A2 BR112022003713A BR112022003713A BR112022003713A2 BR 112022003713 A2 BR112022003713 A2 BR 112022003713A2 BR 112022003713 A BR112022003713 A BR 112022003713A BR 112022003713 A BR112022003713 A BR 112022003713A BR 112022003713 A2 BR112022003713 A2 BR 112022003713A2
Authority
BR
Brazil
Prior art keywords
multimers
treatment
immunocomplex
mediated kidney
recombinant igg
Prior art date
Application number
BR112022003713A
Other languages
English (en)
Inventor
Zhihui Cao Helen
SPIRIG Rolf
Zuercher Adrian
BAZ MORELLI Adriana
Original Assignee
CSL Behring Lengnau AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Behring Lengnau AG filed Critical CSL Behring Lengnau AG
Publication of BR112022003713A2 publication Critical patent/BR112022003713A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

MULTÍMEROS DE Fc DE IgG RECOMBINANTES PARA O TRATAMENTO DE DOENÇAS RENAIS MEDIADAS POR IMUNOCOMPLEXO. A presente invenção refere-se ao uso de multímeros de Fc de IgG recombinantes para o tratamento de distúrbios renais mediados por imunocomplexo e métodos de tratamento de distúrbios renais mediados por imunocomplexo pela administração de tais multímeros.
BR112022003713A 2019-09-13 2020-09-11 Multímeros de fc de igg recombinantes para o tratamento de doenças renais mediadas por imunocomplexo BR112022003713A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19197287 2019-09-13
PCT/EP2020/075432 WO2021048330A1 (en) 2019-09-13 2020-09-11 Recombinant igg fc multimers for the treatment of immune complex-mediated kidney disorders

Publications (1)

Publication Number Publication Date
BR112022003713A2 true BR112022003713A2 (pt) 2022-08-09

Family

ID=68084577

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022003713A BR112022003713A2 (pt) 2019-09-13 2020-09-11 Multímeros de fc de igg recombinantes para o tratamento de doenças renais mediadas por imunocomplexo

Country Status (9)

Country Link
US (1) US20220332847A1 (pt)
EP (1) EP4028415A1 (pt)
JP (1) JP2022547692A (pt)
KR (1) KR20220062084A (pt)
CN (1) CN114401985A (pt)
AU (1) AU2020344164A1 (pt)
BR (1) BR112022003713A2 (pt)
CA (1) CA3150680A1 (pt)
WO (1) WO2021048330A1 (pt)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
GB9720054D0 (en) 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
US7989594B2 (en) 2003-07-01 2011-08-02 Celltech R & D Limited Modified antibody fab fragments
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
BRPI0515230A (pt) * 2004-08-19 2008-07-15 Genentech Inc polipeptìdeos, anticorpos e ácidos nucléicos isolados, composições, vetor de expressão, células hospedeiras isoladas, método para a produção de um anticorpo, artigos manufaturados, métodos de tratamento e para o alìvio de disfunções, métodos de produção e de seleção de um polipeptìdeo, anticorpo de ligação cd20 humanizado, anticorpo anti-her2 isolado e usos de um anticorpo
WO2008151088A2 (en) 2007-06-01 2008-12-11 University Of Maryland, Baltimore Immunoglobulin constant region fc receptor binding agents
TR201906652T4 (tr) 2010-07-28 2019-05-21 Gliknik Inc Kademeli multimerize immünoglobülin fc bileşimleri oluşturmak için doğal insan protein fragmanları içeren füzyon proteinleri.
JP2015506372A (ja) 2012-01-27 2015-03-02 グリックニック インコーポレイテッド ＩｇＧ２ヒンジドメインを含む融合タンパク質
CN104870055A (zh) 2012-10-17 2015-08-26 利物浦热带医学院 免疫调节蛋白
CA2939198A1 (en) 2014-03-05 2015-09-11 Ucb Biopharma Sprl Multimeric fc proteins
RU2016139022A (ru) 2014-03-05 2018-04-25 Юсб Биофарма Спрл МУЛЬТИМЕРНЫЕ Fc-БЕЛКИ
WO2015168643A2 (en) 2014-05-02 2015-11-05 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc constructs
IL256879B2 (en) 2015-07-24 2024-05-01 Gliknik Inc Fusion proteins of human protein fragments to create ordered multimeric immunoglobulin FC preparations with enhanced complement binding
KR20180100701A (ko) * 2016-01-27 2018-09-11 체에스엘 베링 리컴비넌트 퍼실리티 아게 재조합 IgG Fc 다량체
WO2017172853A1 (en) 2016-03-30 2017-10-05 Ab Biosciences, Inc. Recombinant intravenous immunoglobulin (rivig) compositions and methods for their production and use
EP3464376A4 (en) 2016-05-23 2020-03-18 Momenta Pharmaceuticals, Inc. COMPOSITIONS AND METHODS RELATING TO GENETICALLY MODIFIED FC CONSTRUCTIONS
EP3464347B1 (en) 2016-06-07 2023-05-31 Gliknik Inc. Cysteine-optimized stradomers
KR102624254B1 (ko) 2017-01-06 2024-01-12 모멘타 파머슈티컬스 인코포레이티드 유전자 조작 Fc 작제물에 관한 조성물 및 방법
AU2018382586A1 (en) * 2017-12-14 2020-07-02 CSL Behring Lengnau AG Recombinant igG Fc multimers for the treatment of neuromyelitis optica

Also Published As

Publication number Publication date
US20220332847A1 (en) 2022-10-20
CN114401985A (zh) 2022-04-26
KR20220062084A (ko) 2022-05-13
JP2022547692A (ja) 2022-11-15
WO2021048330A1 (en) 2021-03-18
EP4028415A1 (en) 2022-07-20
CA3150680A1 (en) 2021-03-18
AU2020344164A1 (en) 2022-04-14

Similar Documents

Publication Publication Date Title
CL2018003322A1 (es) Inhibidores peptídicos del receptor de interleucina 23 y sus uso para tratar enfermedades inflamatorias. (divisional solicitud 201800128)
WO2017134302A3 (en) Targeted therapeutic agents and uses thereof
BR112018014668A2 (pt) multímeros de fc de igg recombinante
PH12020552189A1 (en) Fusion proteins comprising progranulin
BR112018011308A2 (pt) anticorpos de peptídeo de beta amiloide anti-n3pglu e usos dos mesmos
CO2017001875A2 (es) Terapia de combinación contra el alzheimer usando anticuerpos anti-n3pglu más un inhibidor bace
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
CY1121734T1 (el) ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ
EP4009948A4 (en) USE OF TGF-ALPHA POLYPEPTIDE OR ANTI-TGF-ALPHA ANTIBODIES TO TREAT DISEASES AND DISORDERS
BR112019002730A2 (pt) acetil-leucina, ou um sal farmaceuticamente aceitável da mesma, para uso em um método de tratamento de uma doença neurodegenetativa
MD3768284T2 (ro) Compoziţii de entrecoccus flagellin pentru utilizare în terapie
MX2020007628A (es) Composiciones y metodos de uso.
MX2018008903A (es) COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA.
BR112022012230A2 (pt) Variantes de progranulina
MX2021003119A (es) Anticuerpos anti-klrg1.
EA201990988A1 (ru) Антитела против chikv и пути их применения
MX2017012397A (es) Anticuerpo que reconoce el peptido t14 de enzima acetilcolinesterasa (ache).
EP4276108A3 (en) Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
EP4048799A4 (en) ADENO-ASSOCIATED VIRUS (AAV) SYSTEMS FOR THE TREATMENT OF PROGRANULIN-ASSOCIATED NEURODEGENERATIVE DISEASES OR DISORDERS
EA202192488A1 (ru) Антитела против tsg-6 и их применения
BR112019006174A2 (pt) proteina terapêutica
BR112016023011A2 (pt) tratamento de câncer gástrico
BR112022004475A2 (pt) Proteínas de fusão nkg2d e usos das mesmas
BR112022003713A2 (pt) Multímeros de fc de igg recombinantes para o tratamento de doenças renais mediadas por imunocomplexo
MX2021015501A (es) Anticuerpos y metodos de uso.